Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutics, Inc. - Common Stock (NQ: ONTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Onconova Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Traws Pharma Announces New Employee Inducement Grants
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics's Earnings: A Preview
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. 
Via Benzinga
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
From Onconova Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
From Onconova Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Onconova Expands Leadership Team with Two Key Appointments
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Encouraging Rigosertib Data Presented at EADV as Late Breaker
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.